A pilot study of relapsed or refractory patients using Velcade (bortezomib) combination chemotherapy in AL amyloidosis (REVEAL)

Trial Profile

A pilot study of relapsed or refractory patients using Velcade (bortezomib) combination chemotherapy in AL amyloidosis (REVEAL)

Completed
Phase of Trial: Phase II

Latest Information Update: 28 Mar 2016

At a glance

  • Drugs Bortezomib (Primary) ; Cyclophosphamide; Dexamethasone; Doxorubicin
  • Indications Amyloidosis
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms REVEAL
  • Most Recent Events

    • 24 Mar 2016 Accrual to date is 13% according to United Kingdom Clinical Research Network record.
    • 01 Aug 2015 Status changed from recruiting to discontinued as reported by European Clinical Trials Database record.
    • 21 Jun 2011 Included for PEC also as has cost-effectiveness as secondary objective but as no further information provided have listed as cost-analysis.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top